Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Photo courtesy of Vital Images

News | ACC | December 22, 2015

December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle...

ROCKET AF, executive committee, secondary analysis, rivaroxaban, FDA recall
News | Antiplatelet and Anticoagulation Therapies | December 17, 2015

December 17, 2015 — The ROCKET AF Clinical Trial Executive Committee announced its secondary analysis of the phase...

News | Pharmaceuticals | November 24, 2015

November 24, 2015 —The U.S. Court of Appeals has overturned a federal circuit court’s decision in The Medicines...

Technology | Pharmaceuticals | November 24, 2015

November 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals’...

wearable Holter monitors, iRhythm, ziopatch, zio patch

iRhythm Technologies Zio Patch was among the first of a new generation of simplified, wearable Holter monitors designed to increase ease of use and patient compliance to increase detection of arrhythmias that may lead to stroke.

Feature | Holter Monitoring Systems | November 16, 2015 | Judy Lenane, RN, MHA

One-third of ischemic strokes are classified as cryptogenic. The classic risk factors for stroke are usually absent...

News | Antiplatelet and Anticoagulation Therapies | November 12, 2015

November 12, 2015 — Preventing blood clots with drugs such as...

Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies | November 11, 2015

November 11, 2015 — Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new...

pulmonary embolism, low-risk PE, rivaroxaban, Xarelto, MERCURY PE trial

Image courtesy of Philips Healthcare

News | Pulmonary Embolism | November 03, 2015

November 3, 2015 — Pulmonary...

RIVER-PCI trial, ranolazine, incomplete revascularization, ICR, post-PCI, TCT 2015
News | Antiplatelet and Anticoagulation Therapies | October 23, 2015

October 23, 2015 — A randomized trial found that ranolazine did not reduce the composite rate of ischemia-driven...

BRAVO 3 trial results, bivalirudin, heparin, anticoagulation, TAVR, TCT 2015
Feature | Antiplatelet and Anticoagulation Therapies | October 20, 2015

October 20, 2015 — Results from the BRAVO 3 trial found that...

Praxbind, Pradaxa reversal agent, FDA approval, emergency situations
Technology | Antiplatelet and Anticoagulation Therapies | October 19, 2015

October 19, 2015 — The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (...

Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies | October 02, 2015

October 2, 2015 — AstraZeneca announced that...

News | Antiplatelet and Anticoagulation Therapies | September 25, 2015

September 25, 2015 – The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical...

Brilinta, expanded indication, long-term use, FDA

Brilinta image courtesy of AstraZeneca

Technology | Antiplatelet and Anticoagulation Therapies | September 15, 2015

September 15, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved Brilinta (...

Overlay Init